比较莫西沙星、左氧氟沙星和加替沙星对肺炎链球菌的突变预防浓度。
Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
机构信息
Department of Pathology, Hershey Medical Center, P.O. Box 850, Hershey, PA 17033, USA.
出版信息
Antimicrob Agents Chemother. 2010 Feb;54(2):673-7. doi: 10.1128/AAC.01353-09. Epub 2009 Dec 14.
Abstract
We tested the propensity of three quinolones to select for resistant Streptococcus pneumoniae mutants by determining the mutant prevention concentration (MPC) against 100 clinical strains, some of which harbored mutations in type II topoisomerases. Compared with levofloxacin and gemifloxacin, moxifloxacin had the lowest number of strains with MPCs above the susceptibility breakpoint (P<0.001), thus representing a lower selective pressure for proliferation of resistant mutants. Only moxifloxacin gave a 50% MPC (MPC50) value (1 microg/ml) within the susceptible range.
摘要
我们通过测定 100 株临床分离株的突变预防浓度（MPC）来检测三种喹诺酮类药物选择耐药肺炎链球菌突变株的倾向性，这些分离株中有些含有 II 型拓扑异构酶突变。与左氧氟沙星和加替沙星相比，莫西沙星有更高比例的菌株 MPC 值高于药敏折点（P<0.001），这表明其对耐药突变株的选择压力更低。只有莫西沙星在敏感范围内（MPC50 值为 1μg/ml）得到 50% MPC 值。
相似文献
1
Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
Antimicrob Agents Chemother. 2010 Feb;54(2):673-7. doi: 10.1128/AAC.01353-09. Epub 2009 Dec 14.
2
Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
Antimicrob Agents Chemother. 2007 Apr;51(4):1315-20. doi: 10.1128/AAC.00646-06. Epub 2007 Feb 12.
3
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Antimicrob Agents Chemother. 2006 Jun;50(6):2064-71. doi: 10.1128/AAC.00153-06.
4
In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
Diagn Microbiol Infect Dis. 2003 Dec;47(4):587-93. doi: 10.1016/s0732-8893(03)00152-4.
5
Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
Antimicrob Agents Chemother. 2003 Aug;47(8):2606-14. doi: 10.1128/AAC.47.8.2606-2614.2003.
6
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Int J Antimicrob Agents. 2005 Feb;25(2):163-7. doi: 10.1016/j.ijantimicag.2004.08.017.
7
The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Clin Microbiol Infect. 2005 Sep;11(9):750-8. doi: 10.1111/j.1469-0691.2005.01211.x.
8
Relative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxifloxacin.
J Chemother. 2006 Aug;18(4):373-8. doi: 10.1179/joc.2006.18.4.373.
9
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
Antimicrob Agents Chemother. 2007 Nov;51(11):4196-201. doi: 10.1128/AAC.00827-07. Epub 2007 Sep 17.
10
In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
Diagn Microbiol Infect Dis. 2008 Feb;60(2):155-61. doi: 10.1016/j.diagmicrobio.2007.08.005. Epub 2007 Oct 29.
引用本文的文献
1
The activity of danofloxacin plus ceftiofur combination: implications for antimicrobial efficacy and resistance prevention.
Vet Res Forum. 2022 Jun;13(2):149-153. doi: 10.30466/vrf.2020.113272.2696. Epub 2022 Jun 15.
2
Design and virtual screening of novel fluoroquinolone analogs as effective mutant DNA GyrA inhibitors against urinary tract infection-causing fluoroquinolone resistant .
RSC Adv. 2018 Jun 29;8(42):23629-23647. doi: 10.1039/c8ra01854e. eCollection 2018 Jun 27.
3
In vitro susceptibility of four antimicrobials against Riemerella anatipestifer isolates: a comparison of minimum inhibitory concentrations and mutant prevention concentrations for ceftiofur, cefquinome, florfenicol, and tilmicosin.
BMC Vet Res. 2016 Nov 9;12(1):250. doi: 10.1186/s12917-016-0796-3.
4
Molecular Investigation of Quinolone Resistance of Quinolone Resistance-Determining Region in Streptococcus pneumoniae Strains Isolated from Iran Using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism Method.
Osong Public Health Res Perspect. 2014 Oct;5(5):245-50. doi: 10.1016/j.phrp.2014.08.010. Epub 2014 Sep 6.
5
Antibiotic activity against naive and induced Streptococcus pneumoniae biofilms in an in vitro pharmacodynamic model.
Antimicrob Agents Chemother. 2014;58(3):1348-58. doi: 10.1128/AAC.01858-13. Epub 2013 Dec 16.
6
"Ten Commandments" for the Appropriate use of Antibiotics by the Practicing Physician in an Outpatient Setting.
Front Microbiol. 2011 Nov 24;2:230. doi: 10.3389/fmicb.2011.00230. eCollection 2011.
7
Mutant prevention concentrations of four carbapenems against gram-negative rods.
Antimicrob Agents Chemother. 2010 Jun;54(6):2692-5. doi: 10.1128/AAC.00033-10. Epub 2010 Mar 22.
本文引用的文献
1
Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain.
Emerg Infect Dis. 2009 Jun;15(6):905-11. doi: 10.3201/eid1506.080684.
2
In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
Antimicrob Agents Chemother. 2009 Aug;53(8):3572-5. doi: 10.1128/AAC.00176-09. Epub 2009 May 18.
3
Effect of protein binding on the pharmacological activity of highly bound antibiotics.
Antimicrob Agents Chemother. 2008 Nov;52(11):3994-4000. doi: 10.1128/AAC.00427-08. Epub 2008 Sep 8.
4
Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2007 Nov;51(11):3810-5. doi: 10.1128/AAC.01372-06. Epub 2007 Jul 30.
5
Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
J Antimicrob Chemother. 2006 Dec;58(6):1185-92. doi: 10.1093/jac/dkl387. Epub 2006 Oct 5.
6
Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones.
J Chemother. 2006 Aug;18(4):366-72. doi: 10.1179/joc.2006.18.4.366.
7
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Antimicrob Agents Chemother. 2006 Jun;50(6):2064-71. doi: 10.1128/AAC.00153-06.
8
Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.
Int J Antimicrob Agents. 2006 Feb;27(2):120-4. doi: 10.1016/j.ijantimicag.2005.10.005. Epub 2006 Jan 19.
9
Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Antimicrob Agents Chemother. 2005 Apr;49(4):1633-5. doi: 10.1128/AAC.49.4.1633-1635.2005.
10
Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Antimicrob Agents Chemother. 2004 Oct;48(10):3954-8. doi: 10.1128/AAC.48.10.3954-3958.2004.
Zotero 插件